Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer

American Journal of Human Genetics

Volumn 98, Issue 5, 2016, Pages 801-817

  Maxwell, Kara N ^a   Hart, Steven N ^b   Vijai, Joseph ^c   Schrader, Kasmintan A ^d   Slavin, Thomas P ^e,f   Thomas, Tinu ^c   Wubbenhorst, Bradley ^a   Ravichandran, Vignesh ^c   Moore, Raymond M ^b   Hu, Chunling ^b   Guidugli, Lucia ^b   Wenz, Brandon ^a   Domchek, Susan M ^a   Robson, Mark E ^c,g   Szabo, Csilla ^h   Neuhausen, Susan L ^f   Weitzel, Jeffrey N ^e,f   Offit, Kenneth ^c,g   Couch, Fergus J ^b   Nathanson, Katherine L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAYO CLINIC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Division of Clinical Cancer Genetics   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; EXOME; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MIDDLE AGED; OVARY CANCER; PATHOGENICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; WHOLE EXOME SEQUENCING; AGED; BIOLOGY; BREAST TUMOR; DNA SEQUENCE; EVALUATION STUDY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIATION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PROCEDURES; STANDARDS; YOUNG ADULT;

TUMOR MARKER;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOMICS; GUIDELINES AS TOPIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84968902315     PISSN: 00029297     EISSN: 15376605     Source Type: Journal    
DOI: 10.1016/j.ajhg.2016.02.024     Document Type: Article

References (53)

1. M.B. Daly, R. Pilarski, J.E. Axilbund, S.S. Buys, B. Crawford, S. Friedman, J.E. Garber, C. Horton, V. Kaklamani, C. Klein, et al. National comprehensive cancer network Genetic/familial high-risk assessment: breast and ovarian, version 1.2014 J. Natl. Compr. Canc. Netw. 12 2014 1326 1338
2. K.N. Maxwell, and S.M. Domchek Cancer treatment according to BRCA1 and BRCA2 mutations Nat. Rev. Clin. Oncol. 9 2012 520 528
3. K.N. Maxwell, and S.M. Domchek Familial breast cancer risk Curr. Breast Cancer Rep. 5 2013 170 182
4. K. Michailidou, P. Hall, A. Gonzalez-Neira, M. Ghoussaini, J. Dennis, R.L. Milne, M.K. Schmidt, J. Chang-Claude, S.E. Bojesen, M.K. Bolla, et al. Breast and Ovarian Cancer Susceptibility Collaboration Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) kConFab Investigators Australian Ovarian Cancer Study Group GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network Large-scale genotyping identifies 41 new loci associated with breast cancer risk Nat. Genet. 45 2013 353 361, e1-e2
5. F.J. Gracia-Aznarez, V. Fernandez, G. Pita, P. Peterlongo, O. Dominguez, M. de la Hoya, M. Duran, A. Osorio, L. Moreno, A. Gonzalez-Neira, and et al. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles PLoS ONE 8 2013 e55681
6. D.J. Park, F. Lesueur, T. Nguyen-Dumont, M. Pertesi, F. Odefrey, F. Hammet, S.L. Neuhausen, E.M. John, I.L. Andrulis, M.B. Terry, et al. Breast Cancer Family Registry Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer Rare mutations in XRCC2 increase the risk of breast cancer Am. J. Hum. Genet. 90 2012 734 739
7. E. Ruark, K. Snape, P. Humburg, C. Loveday, I. Bajrami, R. Brough, D.N. Rodrigues, A. Renwick, S. Seal, E. Ramsay, et al. Breast and Ovarian Cancer Susceptibility Collaboration Wellcome Trust Case Control Consortium Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer Nature 493 2013 406 410
8. D.J. Park, K. Tao, F. Le Calvez-Kelm, T. Nguyen-Dumont, N. Robinot, F. Hammet, F. Odefrey, H. Tsimiklis, Z.L. Teo, L.B. Thingholm, and et al. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers Cancer Discov. 4 2014 804 815
9. E.R. Thompson, M.A. Doyle, G.L. Ryland, S.M. Rowley, D.Y. Choong, R.W. Tothill, H. Thorne, D.R. Barnes, J. Li, J. Ellul, et al. kConFab Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles PLoS Genet. 8 2012 e1002894
10. J.I. Kiiski, L.M. Pelttari, S. Khan, E.S. Freysteinsdottir, I. Reynisdottir, S.N. Hart, H. Shimelis, S. Vilske, A. Kallioniemi, J. Schleutker, and et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer Proc. Natl. Acad. Sci. USA 111 2014 15172 15177
11. F.S. Hilbers, C.M. Meijers, J.F. Laros, M. van Galen, N. Hoogerbrugge, H.F. Vasen, P.M. Nederlof, J.T. Wijnen, C.J. van Asperen, and P. Devilee Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling PLoS ONE 8 2013 e55734
12. Z.K. Stadler, K.A. Schrader, J. Vijai, M.E. Robson, and K. Offit Cancer genomics and inherited risk J. Clin. Oncol. 32 2014 687 698
13. L. Castéra, S. Krieger, A. Rousselin, A. Legros, J.J. Baumann, O. Bruet, B. Brault, R. Fouillet, N. Goardon, O. Letac, and et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes Eur. J. Hum. Genet. 22 2014 1305 1313
14. F.J. Couch, S.N. Hart, P. Sharma, A.E. Toland, X. Wang, P. Miron, J.E. Olson, A.K. Godwin, V.S. Pankratz, C. Olswold, and et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer J. Clin. Oncol. 33 2015 304 311
15. A.W. Kurian, E.E. Hare, M.A. Mills, K.E. Kingham, L. McPherson, A.S. Whittemore, V. McGuire, U. Ladabaum, Y. Kobayashi, S.E. Lincoln, and et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment J. Clin. Oncol. 32 2014 2001 2009
16. H. LaDuca, A.J. Stuenkel, J.S. Dolinsky, S. Keiles, S. Tandy, T. Pesaran, E. Chen, C.L. Gau, E. Palmaer, K. Shoaepour, and et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients Genet. Med. 16 2014 830 837
17. K.N. Maxwell, B. Wubbenhorst, K. D'Andrea, B. Garman, J.M. Long, J. Powers, K. Rathbun, J.E. Stopfer, J. Zhu, A.R. Bradbury, and et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer Genet. Med. 17 2015 630 638
18. N. Tung, C. Battelli, B. Allen, R. Kaldate, S. Bhatnagar, K. Bowles, K. Timms, J.E. Garber, C. Herold, L. Ellisen, and et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel Cancer 121 2015 25 33
19. L.G. Biesecker, and R.C. Green Diagnostic clinical genome and exome sequencing N. Engl. J. Med. 371 2014 1170
20. D. Chubb, P. Broderick, M. Frampton, B. Kinnersley, A. Sherborne, S. Penegar, A. Lloyd, Y.P. Ma, S.E. Dobbins, and R.S. Houlston Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing J. Clin. Oncol. 33 2015 426 432
21. R.C. Green, J.S. Berg, W.W. Grody, S.S. Kalia, B.R. Korf, C.L. Martin, A.L. McGuire, R.L. Nussbaum, J.M. O'Daniel, K.E. Ormond, et al. American College of Medical Genetics and Genomics ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing Genet. Med. 15 2013 565 574
22. M.T. Scheuner, J. Peredo, J. Benkendorf, B. Bowdish, G. Feldman, L. Fleisher, J.J. Mulvihill, M. Watson, G.E. Herman, and J. Evans Reporting genomic secondary findings: ACMG members weigh in Genet. Med. 17 2015 27 35
23. Y. Yang, D.M. Muzny, F. Xia, Z. Niu, R. Person, Y. Ding, P. Ward, A. Braxton, M. Wang, C. Buhay, and et al. Molecular findings among patients referred for clinical whole-exome sequencing JAMA 312 2014 1870 1879
24. S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W.W. Grody, M. Hegde, E. Lyon, E. Spector, et al. ACMG Laboratory Quality Assurance Committee Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet. Med. 17 2015 405 424
25. S.N. Hart, K.N. Maxwell, T. Thomas, V. Ravichandran, B. Wubberhorst, R.J. Klein, K. Schrader, C. Szabo, J.N. Weitzel, S.L. Neuhausen, and et al. Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes Brief. Bioinform. 2015 bbv075
26. J.P. Kocher, D.J. Quest, P. Duffy, M.A. Meiners, R.M. Moore, D. Rider, A. Hossain, S.N. Hart, and V. Dinu The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation Bioinformatics 30 2014 1920 1922
27. K. Wang, M. Li, and H. Hakonarson ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data Nucleic Acids Res. 38 2010 e164
28. M. Münz, E. Ruark, A. Renwick, E. Ramsay, M. Clarke, S. Mahamdallie, V. Cloke, S. Seal, A. Strydom, G. Lunter, and N. Rahman CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting Genome Med. 7 2015 76
29. P.D. Stenson, E.V. Ball, M. Mort, A.D. Phillips, J.A. Shiel, N.S. Thomas, S. Abeysinghe, M. Krawczak, and D.N. Cooper Human gene mutation database (HGMD): 2003 update Hum. Mutat. 21 2003 577 581
30. M.J. Landrum, J.M. Lee, G.R. Riley, W. Jang, W.S. Rubinstein, D.M. Church, and D.R. Maglott ClinVar: public archive of relationships among sequence variation and human phenotype Nucleic Acids Res. 42 2014 D980 D985
31. X. Liu, X. Jian, and E. Boerwinkle dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations Hum. Mutat. 34 2013 E2393 E2402
32. N. Rahman Realizing the promise of cancer predisposition genes Nature 505 2014 302 308
33. Z. Erlic, M.M. Hoffmann, M. Sullivan, G. Franke, M. Peczkowska, I. Harsch, M. Schott, H.E. Gabbert, M. Valimäki, S.F. Preuss, and et al. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome J. Clin. Endocrinol. Metab. 95 2010 308 313
34. R.A. Toledo, R. Hatakana, D.M. Lourenço Jr., S.C. Lindsey, C.P. Camacho, M. Almeida, J.V. Lima Jr., T. Sekiya, E. Garralda, M.S. Naslavsky, and et al. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility Endocr. Relat. Cancer 22 2015 65 76
35. S.J. Laken, G.M. Petersen, S.B. Gruber, C. Oddoux, H. Ostrer, F.M. Giardiello, S.R. Hamilton, H. Hampel, A. Markowitz, D. Klimstra, and et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC Nat. Genet. 17 1997 79 83
36. S. Alanee, F. Couch, and K. Offit Association of a HOXB13 variant with breast cancer N. Engl. J. Med. 367 2012 480 481
37. S. Yokoyama, S.L. Woods, G.M. Boyle, L.G. Aoude, S. MacGregor, V. Zismann, M. Gartside, A.E. Cust, R. Haq, M. Harland, and et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma Nature 480 2011 99 103
38. M.E. Robson, A.R. Bradbury, B. Arun, S.M. Domchek, J.M. Ford, H.L. Hampel, S.M. Lipkin, S. Syngal, D.S. Wollins, and N.M. Lindor American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility J. Clin. Oncol. 33 2015 3660 3667
39. S. Wienke, K. Brown, M. Farmer, and C. Strange Expanded carrier screening panels-does bigger mean better? J. Community Genet. 5 2014 191 198
40. D.G. MacArthur, T.A. Manolio, D.P. Dimmock, H.L. Rehm, J. Shendure, G.R. Abecasis, D.R. Adams, R.B. Altman, S.E. Antonarakis, E.A. Ashley, and et al. Guidelines for investigating causality of sequence variants in human disease Nature 508 2014 469 476
41. P.S. Atwal, M.L. Brennan, R. Cox, M. Niaki, J. Platt, M. Homeyer, A. Kwan, S. Parkin, S. Schelley, L. Slattery, and et al. Clinical whole-exome sequencing: are we there yet? Genet. Med. 16 2014 717 719
42. K.D. Farwell, L. Shahmirzadi, D. El-Khechen, Z. Powis, E.C. Chao, B. Tippin Davis, R.M. Baxter, W. Zeng, C. Mroske, M.C. Parra, and et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions Genet. Med. 17 2015 578 586
43. H. Lee, J.L. Deignan, N. Dorrani, S.P. Strom, S. Kantarci, F. Quintero-Rivera, K. Das, T. Toy, B. Harry, M. Yourshaw, and et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders JAMA 312 2014 1880 1887
44. V. Shashi, A. McConkie-Rosell, K. Schoch, V. Kasturi, C. Rehder, Y.H. Jiang, D.B. Goldstein, and M.T. McDonald Practical considerations in the clinical application of whole-exome sequencing Clin. Genet. 89 2016 173 181
45. S.L. Sawyer, T. Hartley, D.A. Dyment, C.L. Beaulieu, J. Schwartzentruber, A. Smith, H.M. Bedford, G. Bernard, F.P. Bernier, B. Brais, et al. FORGE Canada Consortium Care4Rare Canada Consortium Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care Clin. Genet. 89 2016 275 284
46. A. Iglesias, K. Anyane-Yeboa, J. Wynn, A. Wilson, M. Truitt Cho, E. Guzman, R. Sisson, C. Egan, and W.K. Chung The usefulness of whole-exome sequencing in routine clinical practice Genet. Med. 16 2014 922 931
47. M.O. Dorschner, L.M. Amendola, E.H. Turner, P.D. Robertson, B.H. Shirts, C.J. Gallego, R.L. Bennett, K.L. Jones, M.J. Tokita, J.T. Bennett, et al. National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project Actionable, pathogenic incidental findings in 1,000 participants' exomes Am. J. Hum. Genet. 93 2013 631 640
48. T. Gambin, S.N. Jhangiani, J.E. Below, I.M. Campbell, W. Wiszniewski, D.M. Muzny, J. Staples, A.C. Morrison, M.N. Bainbridge, S. Penney, and et al. Secondary findings and carrier test frequencies in a large multiethnic sample Genome Med. 7 2015 54
49. J. Jurgens, H. Ling, K. Hetrick, E. Pugh, F. Schiettecatte, K. Doheny, A. Hamosh, D. Avramopoulos, D. Valle, and N. Sobreira Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics Genet. Med. 17 2015 782 788
50. L.M. Amendola, M.O. Dorschner, P.D. Robertson, J.S. Salama, R. Hart, B.H. Shirts, M.L. Murray, M.J. Tokita, C.J. Gallego, D.S. Kim, and et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification Genome Res. 25 2015 305 315
51. J.J. Johnston, W.S. Rubinstein, F.M. Facio, D. Ng, L.N. Singh, J.K. Teer, J.C. Mullikin, and L.G. Biesecker Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes Am. J. Hum. Genet. 91 2012 97 108
52. D. Ng, J.J. Johnston, J.K. Teer, L.N. Singh, L.C. Peller, J.S. Wynter, K.L. Lewis, D.N. Cooper, P.D. Stenson, J.C. Mullikin, L.G. Biesecker NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program Interpreting secondary cardiac disease variants in an exome cohort Circ Cardiovasc Genet 6 2013 337 346
53. M. Robson Multigene panel testing: planning the next generation of research studies in clinical cancer genetics J. Clin. Oncol. 32 2014 1987 1989